The RespiPoints digital health program was associated with a 44% increase in COPD medication adherence in a recently published study
Boehringer Ingelheim and HealthPrize reported at The American Thoracic Society’s 2022 annual meeting the results from a landmark study showing unprecedented improvements in medication adherence in COPD patients
As compared to tightly-matched controls, HealthPrize members had a 44% increase in medication adherence to treatment (P < 0.0001).
HealthPrize members were 2.51 times more likely to be fully adherent to treatment (80% or greater PDC; P < 0.0001).
HealthPrize members had a 47% lower risk of discontinuing their index treatment (P < 0.0001).
HealthPrize members were 82 days more persistent with treatment (P < 0.0001).
The study’s secondary endpoint of mean total healthcare costs were 24% lower in HealthPrize members compared with controls (P = 0.118).